Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;630(8016):429-436.
doi: 10.1038/s41586-024-07502-0. Epub 2024 May 29.

A Gram-negative-selective antibiotic that spares the gut microbiome

Kristen A Muñoz  1   2 , Rebecca J Ulrich  1   2 , Archit K Vasan  3   4   5 , Matt Sinclair  3   4 , Po-Chao Wen  3   4   5 , Jessica R Holmes  6 , Hyang Yeon Lee  1   2 , Chien-Che Hung  7   8 , Christopher J Fields  6 , Emad Tajkhorshid  1   3   4   5 , Gee W Lau  9 , Paul J Hergenrother  10   11   12
Affiliations

A Gram-negative-selective antibiotic that spares the gut microbiome

Kristen A Muñoz et al. Nature. 2024 Jun.

Abstract

Infections caused by Gram-negative pathogens are increasingly prevalent and are typically treated with broad-spectrum antibiotics, resulting in disruption of the gut microbiome and susceptibility to secondary infections1-3. There is a critical need for antibiotics that are selective both for Gram-negative bacteria over Gram-positive bacteria, as well as for pathogenic bacteria over commensal bacteria. Here we report the design and discovery of lolamicin, a Gram-negative-specific antibiotic targeting the lipoprotein transport system. Lolamicin has activity against a panel of more than 130 multidrug-resistant clinical isolates, shows efficacy in multiple mouse models of acute pneumonia and septicaemia infection, and spares the gut microbiome in mice, preventing secondary infection with Clostridioides difficile. The selective killing of pathogenic Gram-negative bacteria by lolamicin is a consequence of low sequence homology for the target in pathogenic bacteria versus commensals; this doubly selective strategy can be a blueprint for the development of other microbiome-sparing antibiotics.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Maier, L. et al. Unravelling the collateral damage of antibiotics on gut bacteria. Nature 599, 120–124 (2021). - PubMed - PMC - DOI
    1. Lynch, S. V. & Pedersen, O. The human intestinal microbiome in health and disease. New Eng. J. Med. 375, 2369–2379 (2016). - PubMed - DOI
    1. Schubert, A. M., Sinani, H. & Schloss, P. D. Antibiotic-induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against Clostridium difficile. mBio 6, e00974 (2015). - PubMed - PMC - DOI
    1. Owens, R. C. Jr., Donskey, C. J., Gaynes, R. P., Loo, V. G. & Muto, C. A. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin. Infect. Dis. 46, S19–S31 (2008). - PubMed - DOI
    1. Iizumi, T., Battaglia, T., Ruiz, V. & Perez Perez, G. I. Gut microbiome and antibiotics. Arch. Med. Res. 48, 727–734 (2017). - PubMed - DOI

MeSH terms

LinkOut - more resources